NAD+

An intravenous NAD+ trial in ischemic heart failure reports improved left ventricular ejection fraction. It did not detect a clear reduction in major cardiac and cerebrovascular events.

A change in a laboratory marker, a test score and everyday function are different outcomes. A statistically detectable result does not by itself tell us whether someone would notice a worthwhile difference.

Check the measured endpoint, comparison and study population. The full profile preserves effect estimates and the source's clinical-significance assessment, including when that assessment is not supplied.

The claim to test: An intravenous disease-specific biomarker result establishes benefits from oral NAD+ products.

What the reviewed records say:

The gap: The paper defines its primary endpoint inconsistently. Registry reconciliation and broader safety and literature reviews remain open.

Durability, effects in other populations and healthy-lifespan outcomes need their own evidence.

Independent replication, meaningful human outcomes, longer follow-up and better safety reporting would make these results easier to interpret.

The paper defines its primary endpoint inconsistently. Registry reconciliation and broader safety and literature reviews remain open.